# US 2010/0135981 A1 · Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0135981 A1
- Document ID: US20100135981A1
- Status: Published application
- Kind: A1
- Application number: 12/518,855
- Filed: 2007-12-12
- Published: 2010-06-03
- Earliest claimed: 2006-12-13
- Assignees: Hansa Medical AB
- Inventors: Lars Bjorck; Mattias Collin; Arne Olsen; Rikard Holmdahl; Kutty Selva Nandakumar; Oonagh Shannon
- Web page: https://patentgrep.com/patent/US20100135981A1

## CPC

- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/08: for nausea, cinetosis or vertigo; Antiemetics
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 5/06: of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/18: of the parathyroid hormones
- A61P 5/40: Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A method of treating or preventing a disease or condition mediated by IgG antibodies in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide.

### Claim 14

A method of treating, ex vivo, blood taken from a patient suffering from a disease or condition mediated by IgG antibodies, comprising contacting the blood with an EndoS polypeptide.

### Claim 15 (depends on 14)

A method according to claim 14, wherein the blood is returned to the patient after contacting it with said EndoS polypeptide.

### Claim 16 (depends on 13)

A method according to claim 13, wherein said EndoS polypeptide comprises:
(a) the amino acid sequence of SEQ ID NO: 1;
(b) a variant thereof having at least 50% identity to the amino acid sequence of SEQ ID NO: 1 and having IgG endoglycosidase activity; or
(c) a fragment of either thereof having IgG endoglycosidase activity.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said polypeptide consists of the sequence shown in SEQ ID NO: 1.

### Claim 18 (depends on 13)

The method according to claim 13, wherein said polynucleotide comprises:
(a) the coding sequence of SEQ ID NO: 3;
(b) a sequence which is degenerate as a result of the genetic code to the sequence as defined in (a);
(c) a sequence having at least 60% identity to a sequence as defined in (a) or (b) and which encodes a polypeptide having IgG endoglycosidase activity; or
(d) a fragment of any one of the sequences as defined in (a), (b) or (c) which encodes a polypeptide having IgG endoglycosidase activity.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said polynucleotide consists of the nucleic acid sequence shown in SEQ ID NO: 3.

### Claim 20 (depends on 13)

The method of claim 13, wherein the disease or condition is an autoimmune disease, transplant rejection, post-operative treatment or acquired haemophilia.

### Claim 21 (depends on 20)

The method according to claim 20, wherein said autoimmune disease is Addison's disease, alopecia greata, ankylosing spondilitis, antiphospholipid syndrome, aplastic anaemia, autoimmune gastritis, autoimmune hearing loss, autoimmune haemolytic anaemias, autoimmune hepatitis, autoimmune hypoparathyroidism, autoimmune hypophysitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome, autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune polyendocrinopathy, Beçhet's disease, bullous pemphigoid, cardiomyopathy, chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, coeliac disease, Crohn's disease, CREST syndrome, Degos disease, epidermolysis bullosa acquisita, essential mixed cryoglobulinaemia, giant cells arteritis, glomerulonephritis, Goodpasture's syndrome, Graves' disease, Guillan-Barre syndrome, Hashimoto's thyroiditis, idiopathic thrombocytopenic purpura, inflammatory bowel disease, Kawasaki's disease, Meniere's syndrome, mixed connective tissue disease, Mooren's ulcer, multiple sclerosis, myasthenia gravis, pemphigus foliaceous, pemphigus vulgaris, pernicious anaemia, polyarteritis nodosa, polyglandular autoimmune syndrome type 1 (PAS-1), polyglandular autoimmune syndrome type 2 (PAS-2), polyglandular autoimmune syndrome type 3 (PAS-3), polymyositis/dermatomyositis, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's syndrome, Reiter's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, subacute thyroiditis, sympathetic opthalmia, systemic lupus erythematosus, Takayasu's arteritis, type 1 diabetes mellitus, vitiligo, Vogt-Koyanagi-Harada disease or Wegener's granulomatosis.

### Claim 22 (depends on 21)

The method according to claim 21, wherein said autoimmune disease is rheumatoid arthritis.

### Claim 23 (depends on 21)

The method according to claim 21, wherein said autoimmune disease is systemic lupus erythematosus.

### Claim 24 (depends on 21)

The method according to claim 21, wherein said autoimmune disease is idiopathic thrombocytopenic purpura.

### Claim 25 (depends on 20)

The method according to claim 20, wherein said transplant rejection is allograft or xenograft rejection.
